Braveheart Bio, Inc. - Common Stock (BRVE)

Braveheart Bio (NASDAQ:BRVE) presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances the treatment through late-stage development for hypertrophic cardiomyopathy. The data, presented with partner Hengrui a

Insiders are buying shares of Braveheart Bio, BlossomHill Therapeutics and Elanco, three health care stocks with differing risk profiles, analyst ratings, and pipeline catalysts ahead.

Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close.

Insider exercise expanded his direct stake by 16% to 609,519 shares, bringing total beneficial ownership to ~760,000 shares valued at $22.8 million.

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.